At a press confernce at SABCS 2012, Prof Piccart presents data that conculdes one year of adjuvant trastuzumab should remain the standard of care for patients with HER2-postive early-stage breast cancer, according to data from the phase III HERA trial, which compared the efficacy and safety of one year and two years of treatment.